INS and type 2 diabetes mellitus: Sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin were also examined when added to on-going therapy with insulin in subjects with type 2 diabetes in 24–26 week placebo-controlled studies with a total number of 3,196 subjects [Table 2; (89–93)].